US2022073897A1PendingUtilityA1

Artificial ribosomes for fully programmable synthesis of nonribosomal peptides

Assignee: UNIV ARIZONA STATEPriority: Jan 11, 2018Filed: Oct 26, 2021Published: Mar 10, 2022
Est. expiryJan 11, 2038(~11.5 yrs left)· nominal 20-yr term from priority
C12N 9/93C12P 21/02C12N 15/11C12P 17/00C12Y 603/02C12P 7/6409C12N 2795/10322C12N 2740/16022C12N 2740/16222C12N 15/113C07K 14/47C07K 2319/00C12N 2740/10022C12N 2310/16C07K 14/005
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein, in some embodiments, are artificial ribosomes that synthesize nonribosomal peptides, polyketides, and fatty acids with full control over peptide sequence. Also provided herein are methods for programmed synthesis of nonribosomal peptides, polyketides, and fatty acids. In particular, provided herein are methods for scalable synthesis of a wide range of antibacterial, antifungal, antiviral, and anticancer compounds.

Claims

exact text as granted — not AI-modified
1 .- 14 . (canceled) 
     
     
         15 . A molecular assembly line comprising:
 (a) a synthetic RNA scaffold that comprises at least two aptamers, wherein each aptamer comprises a polypeptide binding site; and   (b) at least two fusion proteins, each fusion protein comprising a polyketide synthase (PKS) or fatty acid synthase (FAS) module fused to a RNA-binding peptide that specifically binds to the polypeptide binding site of at least one aptamer within the synthetic RNA scaffold,   
       wherein the synthetic RNA scaffold and the at least two fusion proteins form a complex. 
     
     
         16 . The molecular assembly line of  claim 15 , wherein the synthetic RNA scaffold is a tRNA analog. 
     
     
         17 . The molecular assembly line of  claim 15 , wherein at least one fusion protein comprises a RNA-binding peptide selected from Lambda(G1N2R4), P22N, RevN7D, HTLV-1-Rex, and BIV-Tat. 
     
     
         18 . The molecular assembly line of  claim 17 , wherein at least one RNA binding peptide binds to an aptamer sequence within a tRNA analog. 
     
     
         19 . A synthetic nucleic acid sequence encoding the molecular assembly line of  claim 15 . 
     
     
         20 . A biological cell comprising the synthetic nucleic acid sequence of  claim 19 . 
     
     
         21 . A method for assembling the molecular assembly line of  claim 15 , the method comprising:
 (a) providing the molecular assembly line to a cell-free expression system; and   (b) incubating the cell-free system containing the molecular assembly line under conditions wherein the at least two fusion proteins are able to bind to the synthetic RNA scaffold.   
     
     
         22 . The method of  claim 21 , wherein the synthetic RNA scaffold comprises tRNA analogs. 
     
     
         23 . The method of  claim 21 , wherein at least one RNA-binding peptide comprises an RNA-binding domain from a protein selected from Lambda N, P22N, RevN7D, HTLV-1-Rex, and BIV-Tat. 
     
     
         24 . The method of  claim 23 , wherein at least one RNA-binding peptide binds to an aptamer sequence within a tRNA analog.

Join the waitlist — get patent alerts

Track US2022073897A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.